Vol. 2 No. 6 (2022): June
Health Technology Reviews

Dapagliflozin for Chronic Kidney Disease

Published June 8, 2022

Key Messages

  • Recent, large, high-quality trials have demonstrated some benefits of dapagliflozin for the treatment of chronic kidney disease (most often in patients with Type II diabetes) as compared to placebo.
  • Data describing the clinical effectiveness of dapagliflozin has identified both relative benefits and no differences compared to placebo in various measures of renal and cardiovascular health and function, as well as health care utilization, mortality and adverse events.
  • A large proportion of the available data has been generated from the same randomized controlled trial that has recently been reported in multiple publications describing various patient subgroups and outcomes.
  • No evidence was identified describing the cost-effectiveness of dapagliflozin for the treatment of patients with chronic kidney disease.